July 10, 2025 -
TORONTO, CANADA – July 10, 2025 – MolecuLight Inc., a global pioneer in point-of-care fluorescence imaging for wound care, today announced the appointment of Dr. Julia Wright, MD, FACP, as its new Chief Medical Officer (CMO). Dr. Wright, an exceptionally respected physician with a distinguished 25-year career
… Read MoreJune 26, 2025 -
TORONTO, CANADA – June 26, 2025 – MolecuLight Inc., a global pioneer in point-of-care fluorescence imaging for wound care, proudly announces the publication of a landmark systematic review by researchers at Trinity College Dublin and the Royal College of Surgeons in Ireland (RCSI). Titled “The Clinical Utility
… Read MoreJune 12, 2025 -
Toronto, CANADA and Taipei, TAIWAN – June 12, 2025 – MolecuLight Inc., a global pioneer in point-of-care fluorescence imaging for wound care, and its Taiwanese distributor, Healtdeva Company Ltd., congratulate researchers at Shuang-Ho Hospital in Taipei, Taiwan on their publication of groundbreaking findings using MolecuLight. The
… Read MoreJune 4, 2025 -
Toronto, Canada – June 4, 2025 – MolecuLight Inc., a global pioneer in point-of-care fluorescence imaging for rapid detection of infection causing bacteria in wounds, is pleased to announce its participation in the Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM), taking place in New Orleans,
… Read MoreApril 30, 2025 -
Toronto, Canada – April 30, 2025 – MolecuLight Inc., a global pioneer in point-of-care fluorescence imaging for rapid detection of infection causing bacteria in wounds, today announced the immediate availability of its new Thermal Imaging Module for the MolecuLightDX™ fluorescence imaging platform. This innovative clip-on module allows
… Read MoreApril 29, 2025 -
Toronto, Canada – April 29, 2025 – MolecuLight Inc., a global pioneer in point-of-care fluorescence imaging for rapid detection of infection causing bacteria in wounds, and DocNow, an innovative post-acute Electronic Health Record (EHR) platform, today announced their integration for the MolecuLightDX™ device.
This powerful collaboration will
… Read MoreApril 8, 2025 -
Toronto, Canada – April 8th, 2025 – MolecuLight, a global pioneer in point-of-care fluorescence imaging for rapid bacterial detection in wounds, announces its presence at the American Burn Association (ABA) Annual Meeting in Phoenix, AZ, April 8-11. MolecuLight will showcase its innovative fluorescence imaging systems that empower
… Read MoreApril 3, 2025 -
Toronto, Canada – April 3rd, 2025 – A groundbreaking study published in the Journal of Vascular Surgery: Venous and Lymphatic Disorders has unveiled a significant relationship between bacterial load and pain in patients with venous leg ulcers (VLUs), showcasing the potential of MolecuLight’s fluorescence imaging technology to
… Read MoreFebruary 28, 2025 -
Pittsburgh, PA – 2/28/2025 – MolecuLight Inc., the leader in point-of-care fluorescence imaging devices for wound care, is excited to announce its participation in the 2025 Cellular, Acellular, and Matrix-like Products (CAMPs) Wound Care Summit, held from February 28th to March 2nd in Fort Lauderdale, Florida. In
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2025
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.